TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33721300

Group type: EXPERIMENTAL
Intervention: Sitting thigh position with leg bent
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sitting thigh position with leg straight
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Laying position with leg bent first
Number of subjects: 8

Group type: COMPARATOR
Intervention: Laying position with leg straight first
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sitting arm position with arm bent
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sitting arm position with arm straight
Number of subjects: 8
Study: 35710164

Group type: EXPERIMENTAL
Intervention: Fruit-rich diet (FRD) with at least 4 servings of fruits daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group with less than 2 servings of fruits/day
Number of subjects: 80
Study: 34170090

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody against IBV M41 S1 protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect competitive enzyme-linked immunosorbent assay
Number of subjects: 0
Study: 32756593

Group type: EXPERIMENTAL
Intervention: Tinnitus Focus Condition (TFC)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Body Focus Condition (BFC)
Number of subjects: 67
Study: 35475721

Group type: EXPERIMENTAL
Intervention: Antenatal education regarding milk expression
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 61
Study: 34704710

Group type: COMPARATOR
Intervention: Lidocaine (LIDO group)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Dexmedetomidine (DEX group)
Number of subjects: 91
Study: 32713775

Group type: EXPERIMENTAL
Intervention: Low risk DCIS (non-operated)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: High risk DCIS (non-operated)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Low risk DCIS (overall)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: High risk DCIS (overall)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Overall DCIS cohort
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Low risk DCIS (surgery not received)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: High risk DCIS (surgery not received)
Number of subjects: 1391
Study: 33256727

Group type: EXPERIMENTAL
Intervention: Museum-based arts
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hospital-based arts
Number of subjects: 34

Group type: COMPARATOR
Intervention: Hospital-based conventional education
Number of subjects: 34
Study: 37217585

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring using wearable devices
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring using smartphones
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard model (data collected up to discharge)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Enhanced model (standard model + RPM data)
Number of subjects: 500
Study: 33121832

Group type: EXPERIMENTAL
Intervention: Topical tetracaine applied every 30 minutes as needed for 24 hours
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo applied every 30 minutes as needed for 24 hours
Number of subjects: 118
Study: 32932244

Group type: EXPERIMENTAL
Intervention: Automated HFO detections with higher skewness of the curvature (skewCurve)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Redacting putative false positive HFO detections
Number of subjects: 16
Study: 34942092

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second intravenous immunoglobulin
Number of subjects: 0
Study: 33712841

Group type: EXPERIMENTAL
Intervention: Lower educational attainment (measured by genetic risk scores)
Number of subjects: 190573

Group type: EXPERIMENTAL
Intervention: Higher body mass index (measured by genetic risk scores)
Number of subjects: 190573
Study: 32819191

Group type: EXPERIMENTAL
Intervention: Caffeine-nap (200 mg caffeine prior to a 30 min nap)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (decaffeinated coffee prior to a 30 min nap)
Number of subjects: 6
Study: 36380299

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) plus usual care (UC)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 188
Study: 33088309

Group type: EXPERIMENTAL
Intervention: Vaginal administration of misoprostol (600 μg every 6 hours, maximum of 4 doses)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Sublingual administration of misoprostol (600 μg every 6 hours, maximum of 4 doses)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Oral administration of misoprostol (600 μg every 6 hours, maximum of 4 doses)
Number of subjects: 172

Group type: COMPARATOR
Intervention: All groups (Vaginal, Sublingual, Oral)
Number of subjects: 172
Study: 35173025

Group type: EXPERIMENTAL
Intervention: TTM-based foot care program (6 months)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study: 33753329

Group type: EXPERIMENTAL
Intervention: TAF/FTC 25/200 mg once daily (QD) on days 1 through 21; GSK3640254 200 mg QD added on days 15 through 21
Number of subjects: 16

Group type: COMPARATOR
Intervention: TAF/FTC 25/200 mg once daily (QD) on days 1 through 21
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GSK3640254 200 mg QD
Number of subjects: 16
Study: 35131614

Group type: EXPERIMENTAL
Intervention: Wingman-Connect Program (W-CP)
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Active control (stress management training)
Number of subjects: 1485
Study: 33736819

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 3730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study: 32700995

Group type: EXPERIMENTAL
Intervention: NaI (20 mg/kg, PO, 2 doses 72 hours apart; n = 211)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Untreated controls (216)
Number of subjects: 434
Study: 35670064

Group type: EXPERIMENTAL
Intervention: Active 2 mA tDCS (N = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham tDCS (N = 14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Individualized reverse‐calculation doses
Number of subjects: 28
Study: 32321707

Group type: EXPERIMENTAL
Intervention: BaSAT intervention
Number of subjects: 100
Study: 32660872

Group type: EXPERIMENTAL
Intervention: TTNS + VS (n = 54)
Number of subjects: 106

Group type: COMPARATOR
Intervention: TTNS (n = 52)
Number of subjects: 106
Study: 33472996

Group type: EXPERIMENTAL
Intervention: Endostar combined with chemotherapy (gemcitabine plus cisplatin or docetaxel plus cisplatin)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (gemcitabine plus cisplatin or docetaxel plus cisplatin)
Number of subjects: 44
Study: 33273297

Group type: EXPERIMENTAL
Intervention: 20% sample of Medicare beneficiaries with a cutoff of 6 patients shared between 2 primary care providers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100% data within a small area geographic boundary (PCSAs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 20% sample of Medicare beneficiaries
Number of subjects: 100

Group type: COMPARATOR
Intervention: 100% data from statewide
Number of subjects: 100
Study: 35731506

Group type: EXPERIMENTAL
Intervention: Early CR (2 weeks after sternotomy)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual-care CR (6 weeks after sternotomy)
Number of subjects: 158
Study: 33075711

Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sham needling
Number of subjects: 102
Study: 36403898

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic and resistance training (HIART) program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (60-min education session)
Number of subjects: 82
Study: 33587443

Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 36219142

Group type: EXPERIMENTAL
Intervention: Acupressure (15-minute sessions in the morning/evening for 3 days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pump milking (control group, only milked in the mornings and evenings)
Number of subjects: 64
Study: 33712030

Group type: EXPERIMENTAL
Intervention: iPSC-MSCs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BMSCs
Number of subjects: 40

Group type: COMPARATOR
Intervention: MPS + BMSCs
Number of subjects: 40

Group type: COMPARATOR
Intervention: MPS + iPSC-MSCs
Number of subjects: 40

Group type: COMPARATOR
Intervention: normal control group
Number of subjects: 40
Study: 36441433

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day for 16 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 33458819

Group type: EXPERIMENTAL
Intervention: Intra-vaginal isosorbide mononitrate (IMN)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 32736540

Group type: EXPERIMENTAL
Intervention: Standard of care plus chemotherapy (4 cycles of 3 weeks of intravenous chemotherapy with doxorubicin in combination with dacarbazine or ifosfamide according to histologic subtype)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Standard of care plus chemotherapy
Number of subjects: 250
Study: 35437881

Group type: EXPERIMENTAL
Intervention: Topical oxygen therapy and standard of care (TOT/SOC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard of care alone (SOC)
Number of subjects: 29
Study: 32050232

Group type: EXPERIMENTAL
Intervention: Self-reported smoking status
Number of subjects: 11435

Group type: EXPERIMENTAL
Intervention: Cotinine-verified smoking status
Number of subjects: 11435

Group type: EXPERIMENTAL
Intervention: Survey-cotinine-verified smoking status (SCS)
Number of subjects: 11435
Study: 34320218

Group type: EXPERIMENTAL
Intervention: Supratotal resection (SpTR)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Gross total resection (GTR)
Number of subjects: 21
Study: 32005283

Group type: EXPERIMENTAL
Intervention: Daesiho-tang (DST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 36103844

Group type: EXPERIMENTAL
Intervention: Su Jok seed therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 47
Study: 34227053

Group type: EXPERIMENTAL
Intervention: kMCT drink, BrainXpert Energy Complex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33050905

Group type: EXPERIMENTAL
Intervention: Fruquintinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32770520

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 35094695

Group type: EXPERIMENTAL
Intervention: Fasting blood glucose to high-density lipoprotein cholesterol (FG/HDL-C) ratio in the highest quartile
Number of subjects: 11284
Study: 34139746

Group type: EXPERIMENTAL
Intervention: 2'‐fucosyllactose (2'FL)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mix of 2'FL and lacto‐N‐neotetraose
Number of subjects: 75

Group type: COMPARATOR
Intervention: Glucose placebo
Number of subjects: 75
Study: 32536270

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation
Number of subjects: 135

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: All groups (anodal, cathodal, sham)
Number of subjects: 135
Study: 34216552

Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IT convergence exercise
Number of subjects: 40
Study: 32151753

Group type: EXPERIMENTAL
Intervention: Home-visit group (received enhanced clinical care, detailed home assessment, and four additional home visits over roughly one year)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Clinic-only group (received enhanced clinical care)
Number of subjects: 263
Study: 36166515

Group type: EXPERIMENTAL
Intervention: C‐MAC® (Macintosh style blade) videolaryngoscope
Number of subjects: 260

Group type: COMPARATOR
Intervention: Direct laryngoscopy using the Macintosh laryngoscope
Number of subjects: 260
Study: 34340607

Group type: EXPERIMENTAL
Intervention: BNO 1200 (thyme/ivy herbal fluid extract)
Number of subjects: 730
Study: 33915363

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Random Forest (RF)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ECG-FD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: EMG
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ECG-TD + ECG-FD + EMG
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ECG time-domain, ECG frequency-domain, EMG, VC, SBP, pulse
Number of subjects: 45
Study: 34951464

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (oral; 0.43 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 20
Study: 33721439

Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 136
Study: 33843514

Group type: EXPERIMENTAL
Intervention: Panic disorder
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Generalised anxiety disorder, dysthymia, or mixed symptoms (cothymia)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: All patients with personality dysfunction at entry
Number of subjects: 210

Group type: COMPARATOR
Intervention: No personality dysfunction at entry
Number of subjects: 210
Study: 35089655

Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise training (3 sessions/week for 6 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study: 34047835

Group type: EXPERIMENTAL
Intervention: Liquid platelet-rich fibrin (liquid-PRF) with bovine-derived xenograft
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bovine-derived xenograft alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (liquid-PRF and control)
Number of subjects: 40
Study: 33234578

Group type: EXPERIMENTAL
Intervention: Personalized treatment strategy using monoclonal antibodies combined with optimally sequenced chemotherapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 68
Study: 32236154

Group type: EXPERIMENTAL
Intervention: Deuterated ethyl alcohol (D-C2H5OH)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 34146120

Group type: EXPERIMENTAL
Intervention: NLC‐TRE (tretinoin-loaded nano lipid carriers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TRE cream (0.05% tretinoin cream)
Number of subjects: 0
Study: 34000240

Group type: EXPERIMENTAL
Intervention: PCET
Number of subjects: 510

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 510
Study: 36205275

Group type: EXPERIMENTAL
Intervention: Physiotherapy + NMES
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 80
Study: 34026698

Group type: EXPERIMENTAL
Intervention: Simple exchange message
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 344
Study: 32553836

Group type: EXPERIMENTAL
Intervention: Formula-fed infants with cow milk diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula-fed infants with extensively hydrolyzed protein diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants in the upper quartile for weight gain velocity
Number of subjects: 0
Study: 35859328

Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF as primary prophylactic therapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (rhG-CSF administered when white blood cell count was <2.0 × 10^9/L or absolute neutrophil count <1.0 × 10^9/L)
Number of subjects: 130
Study: 32417822

Group type: EXPERIMENTAL
Intervention: Stretching before delivery trials
Number of subjects: 8

Group type: COMPARATOR
Intervention: No stretching
Number of subjects: 8
Study: 34448477

Group type: EXPERIMENTAL
Intervention: Genetic risk score based on 14 BMI-associated variants
Number of subjects: 11384

Group type: EXPERIMENTAL
Intervention: Individual 14 SNVs as instrumental variables
Number of subjects: 11384
Study: 32404226

Group type: EXPERIMENTAL
Intervention: internet-delivered acceptance and commitment therapy (iACT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: internet-delivered discussion forum (iFORUM)
Number of subjects: 101
Study: 32092160

Group type: EXPERIMENTAL
Intervention: Smartphone application (app)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 380
Study: 33602580

Group type: EXPERIMENTAL
Intervention: Prone recruitment manoeuvres (40 cm H2O peak inspiratory pressure and 20 cm H2O PEEP for 30 s)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prone recruitment manoeuvres
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supine recruitment manoeuvres
Number of subjects: 30
Study: 616667359

Group type: EXPERIMENTAL
Intervention: Intervention promoting adequate and healthy eating for 9 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 32053254

Group type: EXPERIMENTAL
Intervention: Living Well Multicultural‐Lifestyle Management Program (LWM‐LMP)
Number of subjects: 0
Study: 32164612

Group type: EXPERIMENTAL
Intervention: SMS delivery of TB test results
Number of subjects: 10
Study: 32484752

Group type: EXPERIMENTAL
Intervention: SES-RP/NP (modified Sexual Experiences Survey-Short Form Victimization)
Number of subjects: 442

Group type: COMPARATOR
Intervention: SES-SFV (traditional Sexual Experiences Survey-Short Form Victimization)
Number of subjects: 442

Group type: COMPARATOR
Intervention: SVAWS (Severity of Violence Against Women Scales)
Number of subjects: 442
Study: 32933561

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Stretching and toning exercises
Number of subjects: 75

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 75
Study: 35830179

Group type: EXPERIMENTAL
Intervention: Activity tracker and fortnightly health-coaching sessions for 3 months
Number of subjects: 51
Study: 32189364

Group type: EXPERIMENTAL
Intervention: Telbivudine treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon therapy after lamivudine resistance
Number of subjects: 0
Study: 35577281

Group type: EXPERIMENTAL
Intervention: Text messaging program with brief in-person education and 3 months of educational text messages
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Text messaging program
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 221
Study: 33340805

Group type: EXPERIMENTAL
Intervention: Visuospatial distraction (attending phone calls with questions inducing visuospatial processing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conceptual distraction (attending phone calls with questions requiring semantic memory)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-distraction
Number of subjects: 0
Study: 33712919

Group type: EXPERIMENTAL
Intervention: Zoledronate
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 35139272

Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Uncemented hemiarthroplasty
Number of subjects: 1225
Study: 33946085

Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg twice daily with optimized background therapy (OBT)
Number of subjects: 107
Study: 32989898

Group type: EXPERIMENTAL
Intervention: Work-related factors (role conflict, effort, utilization of job skills, reward, social support)
Number of subjects: 807
Study: 32750261

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hib-HepB vaccine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control vaccine (PENTACEL™ or INFANRIX™ hexa)
Number of subjects: 160
Study: 36068618

Group type: EXPERIMENTAL
Intervention: Intensive family-based lifestyle modification programme
Number of subjects: 3682

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3682
Study: 34454654

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 338

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 338
Study: 32321350

Group type: EXPERIMENTAL
Intervention: 1.0 inspired oxygen
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0.21 inspired oxygen
Number of subjects: 25
Study: 36029653

Group type: EXPERIMENTAL
Intervention: FP/bevacizumab + atezolizumab (800 mg 60-min i.v. infusion q2 weeks)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Control (fluoropyrimidine (FP)/bevacizumab)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Experimental (FP/bevacizumab + atezolizumab)
Number of subjects: 445
Study: 32861217

Group type: EXPERIMENTAL
Intervention: Esketamine 84 mg nasal spray twice weekly for 4 weeks with standard of care
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo nasal spray twice weekly for 4 weeks with standard of care
Number of subjects: 230
Study: 34784076

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Magnetic resonance cholangiopancreatography (MRCP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) after negative MRCP
Number of subjects: 50

Group type: COMPARATOR
Intervention: Magnetic resonance cholangiopancreatography (MRCP) after negative EUS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both EUS and MRCP
Number of subjects: 50
Study: 33856570

Group type: EXPERIMENTAL
Intervention: Daily subcutaneous teriparatide (TPD) 20 mcg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cyclic teriparatide (TPD) followed by raloxifene (RLX) 60 mg
Number of subjects: 26
Study: 35509490

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study: 36343657

Group type: EXPERIMENTAL
Intervention: Experimental manipulation promoting more malleable emotion beliefs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 33647946

Group type: EXPERIMENTAL
Intervention: CLIP score (based on cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: CLIP score
Number of subjects: 458